Objectives: Our previous in vitro study showed that 5-(3, 4, 5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) is a novel colchicine binding site inhibitor with potent anti-cancer activity against apoptosis resistance in A549/Taxol cells through mitotic catastrophe (MC). However, the mechanisms underlying apoptosis resistance in A549/Taxol cells remain unknown. To clarify these mechanisms, in the present study, we investigated the molecular mechanisms of apoptosis and autophagy, which are closely associated with MC in BZML-treated A549 and A549/Taxol cells.
Traditionally, the main mode of action of chemotherapeutic drugs is the induction of programmed cell death (PCD), including apoptosis and autophagy. [6] [7] [8] [9] [10] Apoptosis is a major mechanism that eliminates cancer cells through multiple signalling pathways. Cellular redox reactions play a major role in apoptosis. Excessive reactive oxygen species (ROS) can induce the disruption of the mitochondrial membrane potential (MMP) and the release of cytochrome c from mitochondria to cytoplasm, and can trigger caspase-dependent mitochondrial apoptosis. 11, 12 In contrary, GSH, an ROS scavenger, plays a protective role against oxidative agents and leads to apoptosis resistance in cancer cells by eliminating intracellular ROS. 13, 14 Additionally, GSH-based detoxification also causes apoptosis resistance in numerous cancer cells. [15] [16] [17] Thus, excessive ROS production along with GSH depletion can effectively enhance anti-cancer drug activity and overcome drug resistance. [18] [19] [20] Apoptosis has been a prevalent model in anti-cancer drug development, but de-regulated apoptotic signalling often leads to an increase of apoptosis resistance in cancer cells with the progression of treatment. 21, 22 Additionally, autophagy has been proposed as a tumour suppressor, plays a key pro-survival role in cells by eliminating damaged organelles and proteins, and contributes apoptosis resistance in cancer cells. [23] [24] [25] [26] Importantly, the different functional forms of autophagy depend on the genetic background of cells, the microenvironment and the type of drug. 27, 28 Recently, other types of PCD, including necroptosis, MC and senescence, have been reported. 10, [29] [30] [31] MC, a p53-independent apoptosis-like cell death mode to against apoptosis resistance, has received more attention. 10, 30 Generally, drugs cannot fully kill cancer cells by only one type of PCD and, therefore, may easily induce multidrug resistance (MDR). 23, 30 Therefore, developing novel anti-cancer drugs with multiple PCD models is necessary.
Our previous study has shown that 5-(3, 4, 5-trimethoxybenzoyl) -4-methyl-2-(p-tolyl) imidazol (BZML), a novel colchicine-binding site inhibitor, has broad-spectrum anti-cancer activity against various chemo-sensitive or resistant cancer cells in vitro. 10 Importantly, BZML can force cells to die through apoptosis in A549 cells, whereas it mainly drives A549/Taxol cells to die by MC to against apoptosis resistance. 10 However, the apoptosis-resistant mechanisms in A549/ Taxol cells have not been fully understood. In the present study, we elucidate the mechanisms underlying the apoptosis resistance in BZML-treated A549/Taxol cells, which will provide a new reference for using BZML as an anti-cancer drug to overcome drug-resistant NSCLC.
| MATERIAL S AND ME THODS

| Chemical compounds and reagents
BZML was synthesized by our group (the purity ≥98%). Paclitaxel injection was purchased from Cisen Pharmaceutical Co., Ltd and rapamycin (Rapa) were purchased from Selleck Chemicals (Houston, TX, USA). Hoechst 33342, N-acetyl-L-cysteine (NAC), 
| Cell culture
A549 and A549/Taxol cells were grown in RPMI 1640 supplemented with 10% FBS at 37°C with 5% CO 2 in a humidified incubator. A549/ Taxol cells were periodically cultured in 300 nM Taxol to maintain MDR and shifted into Taxol-free medium for 1 week before used. 
| Antitumour effects in vivo
All animal studies were performed in accordance with the guide-
lines of the Animal Experimental Ethics Committee of Shenyang
Pharmaceutical University. Xenograft tumours were generated in 5-week-old male BALB/c nude mice (Huafukang Bioscience Co. Inc., Beijing, P.R.C.) using A549 or A549/Taxol cells (5 × 10 6 cells/mice).
The tumour volumes were calculated by digital calliper measurement using the following formula: (length × width 2 )/2. When the tumour volumes reached 100 mm 3 , mice were randomized into 3 groups that received the following: model (vehicle, 5% ethanol+20% PEG-400+75% saline), Taxol (10 mg/kg, Taxol injection diluted in saline) and BZML (10 mg/kg, dissolved in the same vehicle as the model group).
Mice were intraperitoneally administered these drugs every 3 days.
By the end of the experiment, all tumours and organs were collected and measured.
| Immunohistochemistry assay
The embedded tumour tissue sections were deparaffinated, hydrated and stained with immunohistochemistry for PCNA as previously described. 
| Determination of proliferation inhibitory effect and apoptosis
The proliferation inhibitory effect of BZML was determined by MTT assay as described previously. 7 The apoptosis-like cells were detected by Annexin V-FITC/PI double-staining and analysed by FACS as described previously. 
| Cell morphology changes
The cells were incubated with BZML for 36 hours and photographed using a fluorescence microscope (Olympus, Japan) after Hoechst 33342 staining.
| Cell cycle analysis
Cell cycle was detected by 70% (v/v) ethanol fixing and PI staining as described previously. 10 The samples were analysed by FACS.
| MMP assay
Cells were treated with BZML for indicated time followed by JC-1 staining for 30 minutes at 37°C in the dark. Next, samples were analysed by a fluorescence microscope or FACS.
| Preparation of cytoplasmic and mitochondrial fractions
After BZML treatment for indicated time, the cytoplasm and mitochondria were isolated using Mitochondrial Isolation Kit according to the manufacturer's instructions.
| Caspase-9 activity
Drug-stimulated activity of caspase-9 was measured using the caspase-9 fluorescence metric assay kit according to the manufacturer's instructions. The caspase-9 activity was calculated by the fold of the fluorescence intensity of BZML-treated group to that of control.
| Measurement of GSH and GSSG
Cells were treated with BZML for indicated time. The total GSH and GSSG levels were determined by GSH and GSSG Assay Kit. All steps in the procedure were based on the manufacturer's instructions.
| Immunofluorescence staining
Immunofluorescence analysis was performed as previously described and photographed by confocal microscopy (Nikon C2, Japan). 
| Western blot analysis
Western blot was performed as described previously. 8 Densitometry analysis was done using Image J2 software.
| Statistical analysis
Data are expressed as mean ± SD of three experiments and were assessed through one-way analysis of variance by SPSS 22.0 software. P < .05 was considered as statistical significance.
| RE SULTS
| BZML inhibits the growth of Taxol-sensitive and Taxol-resistant human tumour xenografts in vivo
In this study, A549 cell-bearing mice with BZML or Taxol treatment The slightly decreased body weights in BZML-treated mice could be recovered with the extension of treatment time.
Importantly, according to the viscera index analysis (the ratio of visceral weight to body weight [mg/g]), no differences were observed in the heart, liver, lung and kidney of the mice between the BZML and model groups, suggesting that this compound has low toxicity ( Figure 1E ).
PCNA is a nucleoprotein that localizes to eukaryotic cell nuclei and acts as a proliferative marker. 32, 33 As shown in Figure 1F , high rates of PCNA-positive cells were observed in the model group.
Taxol inhibited the rate of PCNA-positive cells in the tumours of A549 but not A549/Taxol cell-bearing mice. Instead, after treatment with BZML, there was a significant decrease in the rates of PCNApositive cells in tumours of both of these two mice models.
| BZML-induced cell death is dependent on ROS in A549 cells but not in A549/Taxol cells
ROS is well-known to play an important role in inducing cell death. that differs from apoptosis with unique nuclear alterations, such as multi-and/or micro-nucleation. 10 Examination of cell morphology ( Figure 2E ) and the cell cycle assay ( Figure 2F ) showed that NAC also had no influence on the proportion of multi-nucleated cells in BZMLtreated A549/Taxol cells.
| The mitochondrial apoptotic pathway is only activated in BZML-treated A549 cells but not in BZML-treated A549/Taxol cells
In many cases, mitochondrial apoptosis involves the stimulation of ROS production followed by MMP depolarization. 11, 12 Upon JC-1 The mitochondria are known to be important sites for the generation of ROS and the induction of ROS results in oxidative damage to the mitochondria. 11, 12 To clarify the relationship between ROS and MMP, we inhibited ROS by NAC and determined the levels of MMP. As shown in Figure 3A ,B, NAC pretreatment significantly rescued the decrease in MMP compared with the BZML-treated group. Mitochondrial damage is also associated with the release of cytochrome c from mitochondria to cytosol and activates the mitochondrial apoptotic pathway. 12 Our results
showed that cytosolic cytochrome c levels increased while the mi- 60 nM) for indicated time. *P < .05, **P < .01 vs control; ## P < .01 vs BZML-alone-treated group permeabilization can be affected by the Bcl-2 family proteins. 34, 35 We found that BZML could time dependently up-regulate the expression of Bax and down-regulate the expression of Bcl-2 in A549 and A549/Taxol cells ( Figure 3C ). Importantly, caspase-9
acts as a mitochondrial apoptotic pathway effector. 11, 12 In our study, cleaved caspase-9 was only detected in BZML-treated A549 cells ( Figure 3C ). Meanwhile, BZML time dependently enhanced caspase-9 activity in A549 cells, but not in A549/Taxol cells ( Figure 3D) . Further, the caspase-9 inhibitor Z-LEHD-FMK 
| BZML causes GSH depletion and DNA damage in both A549 and A549/Taxol cells
The GSH/GSSG ratio is widely used as an important indicator to evaluate the cellular redox system. [15] [16] [17] As shown in Figure 4A , the GSH/ GSSG ratios were significantly reduced in both BZML-treated A549
and A549/Taxol cells. Interestingly, the constitutive GSH/GSSG ratios were not significantly different between A549 and A549/Taxol cells, suggesting that GSH did not contribute to apoptosis resistance in A549/Taxol cells.
Histone H2AX is known to be phosphorylated at Ser139 (γ-H2AX) immediately after DNA damage. 36, 37 As shown in Figure 4B , the expression levels of γ-H2AX were increased in a time-dependent manner in both BZML-treated A549 and A549/Taxol cells. Meanwhile, pretreatment with NAC protected the BZML-treated A549 and A549/Taxol cells from the DNA damage, a finding that was reflected in the decreased number of γ-H2AX foci formation, confirming that ROS production could regulate DNA damage ( Figure 4C ).
| BZML induces autophagy in both A549 and A549/Taxol cells
Autophagy is often activated during chemotherapy. Here, we used MDC to assess autophagy induction via the accumulation of the MDC-labelled autophagosome. 6 As shown in Figure 5A , Figure 5D ).
In addition, the conversion of LC3 from LC3-I to LC3-II is a characteristic of autophagy. 24, 38, 39 As indicated in Figure 5E , with MC ( Figure 5F ).
| Autophagy plays a protective role in BZMLinduced MC, but not against BZML-induced apoptosis
As autophagy is also a survival mechanism, one can speculate that autophagy induced by anti-cancer drugs might contribute to apoptosis resistance. 26 Next, we investigated the cross-talk between BZML-induced autophagy and apoptosis in A549 cells or MC in A549/Taxol cells, respectively. As shown in Figure 6A Rapa, a classic autophagy accelerant, was used to induce autophagy. 40 As shown in Figure 6D , the number of apoptosis-like cells 
| D ISCUSS I ON
Microtubules are important in maintaining the structure of cells and have become an excellent drug target in chemotherapy.
41-43
Currently, Taxol is widely used in the treatment of NSCLC in the clinics. However, many patients have acquired resistance to Taxol, and even those who initially respond will eventually exhibit MDR. [44] [45] [46] [47] We have confirmed that BZML has potent anti-cancer activity against Taxol-sensitive or Taxol-resistant A549 cells through different death modes in vitro. 10 This paper aimed to evaluate the anticancer activity of BZML in vivo and the mechanism underlying the apoptosis resistance in BZML-treated A549/Taxol cells.
The acquired resistance in cancer cells is often associated with more malignancy, which is reflected by rapid proliferation of cancer cells and poor efficacy of anti-cancer drugs. 48, 49 In our study, the therapeutic dose of Taxol used in A549 cell-bearing mice failed to inhibit tumour growth in A549/Taxol cell-bearing mice.
Meanwhile, the overall size and weight of tumours in the A549/ Taxol cell-bearing mice were greater than in A549 cell-bearing mice under drug-free treatment conditions, suggesting that the tumours of A549/Taxol cell-bearing mice were more malignant than those of A549 cell-bearing mice. Importantly, BZML had potent anticancer activity in both A549 and A549/Taxol cell-bearing mice.
Additionally, the rates of PCNA-positive cells were decreased in both the BZML-treated A549 and A549/Taxol cell-bearing mice.
Further, compared with the model group, the average body weight and the viscera index of mice were not significantly influenced by BZML. These results indicate that BZML exhibits potential anti-cancer effects and low toxicity on Taxol-sensitive or Taxol-
Apoptosis is a major mechanism used to eliminate cancer cells, and the mitochondrial pathway plays an important role in this process. 21 In our study, BZML caused ROS generation and MMP loss followed by the release of cytochrome c from mitochondria to cytosol in A549 and A549/Taxol cells. However, activated caspase-9
was only observed in A549 cells. Moreover, the caspase-9 fluorescence metric assay showed that caspase-9 activity was increased acts as a free radical scavenger and plays a protective role against ROS-mediated anti-cancer effects. [15] [16] [17] Importantly, the overexpression of GSH has been associated with chemo-and radio-resistance in cancer cells. 13, 14 Therefore, GSH depletion is considered to be an effective strategy to sensitize cancer cells to therapy. Here, ROS did not play a role in inducing cell death, and GSH did not contribute to the resistance to mitochondrial apoptosis in A549/Taxol cells;
however, ROS generation could still damage DNA and other cellular components to destroy cellular functions and lead to GSH depletion, which, in part, blocked the occurrence of apoptosis resistance mediated by GSH.
Most studies have reported that autophagy is an important factor for apoptosis resistance. 26, 39 Thus, our study mainly The excellent anti-cancer activity of BZML is worthy of further preclinical research for a promising anti-cancer drug, and autophagy inhibition could potentiate BZML-induced MC to overcome the resistance to mitochondrial apoptosis. These findings may provide a novel therapeutic approach against drug-resistant NSCLC.
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